Endometrial Cancer Trial, Recruiting NCT06527157 Sponsor: PinkDx, Inc. Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT06527157
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed and dated a consent form showing they have been told about all important aspects of the study.
  • People who are willing and able to attend scheduled visits and follow the study plan.
  • People who expect to be available for the full length of the study and can be reached by phone during that time.
  • Women aged 45 and older (with the study aiming for roughly 80% of participants to be over 50).
  • People who have a uterus.
  • People who are currently being investigated for abnormal uterine bleeding or bleeding after menopause, where the cause is being looked into.

Who may not be able to join:

  • Staff members at the trial site who are directly involved in running the study, their family members, or people who work for PinkDx, Inc. or their family members.
  • People with other medical or psychiatric conditions that the trial doctor believes would make participation riskier.
  • Women who have had a hysterectomy (surgical removal of the uterus).
  • Women with a known history of cancer of the uterine lining (endometrial cancer) or uterine sarcoma (a type of uterine cancer).
  • Women who have previously received treatment for endometrial cancer.
  • People who are unable or unwilling to sign the consent form.
  • People where pregnancy is suspected.
  • Women who have used a tampon within 7 days before the sample is collected.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andrea Mariani, MD, Mayo Clinic

Phone: 463-273-7024

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
PinkDx, Inc.
Registry
ClinicalTrials.gov
Start date
30 July 2024
Est. completion
30 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Sensitivity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov